Jennison Associates
EWTX icon

Jennison Associates’s Edgewise Therapeutics EWTX Stock Holding History

Jennison Associates’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-128,746
Closed -$2.83M – 602
2025
Q1 		$2.83M Buy
+128,746
New +$3.38M ﹤0.01% 424

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates's EWTX Position: Q2 2025 in Review

Jennison Associates sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 128,746 shares — an estimated $2.83M sold.

Jennison Associates first reported a position in EWTX in Q1 2025 and held it in 1 quarter. The position peaked at $2.83M in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • Jennison Associates reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 128,746 Edgewise Therapeutics shares in Q2 2025, an estimated $2.83M.
  • Jennison Associates first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 1 quarter.
  • Jennison Associates's Edgewise Therapeutics position peaked at $2.83M in Q1 2025.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.